Cara Therapeutics, Inc.

DB:69C Stock Report

Market Cap: €15.9m

Cara Therapeutics Management

Management criteria checks 2/4

Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 6.25 years. total yearly compensation is $2.92M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth €34.96K. The average tenure of the management team and the board of directors is 3 years and 5.3 years respectively.

Key information

Chris Posner

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage24.9%
CEO tenure3yrs
CEO ownership0.2%
Management average tenure3yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Posner's remuneration changed compared to Cara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$111m

Mar 31 2024n/an/a

-US$123m

Dec 31 2023US$3mUS$728k

-US$119m

Sep 30 2023n/an/a

-US$117m

Jun 30 2023n/an/a

-US$112m

Mar 31 2023n/an/a

-US$84m

Dec 31 2022US$3mUS$700k

-US$85m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$93m

Dec 31 2021US$10mUS$116k

-US$88m

Sep 30 2021n/an/a

US$24m

Jun 30 2021n/an/a

US$8m

Mar 31 2021n/an/a

US$14m

Dec 31 2020US$280kn/a

US$8m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$115m

Mar 31 2020n/an/a

-US$113m

Dec 31 2019US$302kn/a

-US$106m

Sep 30 2019n/an/a

-US$98m

Jun 30 2019n/an/a

-US$85m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$494kn/a

-US$74m

Compensation vs Market: Chris's total compensation ($USD2.92M) is above average for companies of similar size in the German market ($USD471.55K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Posner (54 yo)

3yrs

Tenure

US$2,922,469

Compensation

Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Posner
President3yrsUS$2.92m0.22%
€ 35.0k
Ryan Maynard
Chief Financial Officer2.2yrsUS$1.24m0.015%
€ 2.3k
Derek Chalmers
Co-Founder & Senior Advisor3yrsUS$10.20mno data
Scott Terrillion
Chief Compliance Officer8yrsUS$1.59m0.15%
€ 23.7k
Matthew Murphy
Manager of Investor Relationsno datano datano data

3.0yrs

Average Tenure

57.5yo

Average Age

Experienced Management: 69C's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Posner
President6.3yrsUS$2.92m0.22%
€ 35.0k
Martin Vogelbaum
Independent Chairman & Lead Independent Director14.3yrsUS$519.99k0.20%
€ 31.9k
Graeme Milligan
Member of the Scientific Advisory Boardno datano datano data
Stanley Watson
Member of the Scientific Advisory Boardno datano datano data
James Kauer
Member of the Scientific Advisory Boardno datano datano data
Philip Portoghese
Member of the Scientific Advisory Boardno datano datano data
Jeffrey L. Ives
Independent Director10.3yrsUS$272.49k0.087%
€ 13.9k
Helen Boudreau
Independent Director1.3yrsUS$376.01k0%
€ 0
Susan Shiff
Independent Director4.4yrsUS$262.49k0.094%
€ 15.0k
Lisa von Moltke
Independent Director2yrsUS$254.99k0.059%
€ 9.4k

5.3yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 69C's board of directors are considered experienced (5.3 years average tenure).